Aliskiren and Amlodipine in the Management of Essential Hypertension: Meta-analysis of Randomized Controlled Trials

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2013 Aug 8

PMID 23922924

Citations 7

Authors

Yukai Liu

Ken Chen

Xun Kou

Yu Han

Lin Zhou

Chunyu Zeng

Affiliations

Soon will be listed here.

Abstract

Background: Aliskiren is a novel renin-angiotensin aldosterone system (RAAS) inhibitor, the combination therapy of aliskiren and amlodipine for blood pressure control have been reported recently. The primary objective of this analysis is to review recently reported randomized controlled trials (RCTs) to compare antihypertensive effects and adverse events between mono (amlodipine or aliskiren alone) and combination therapy of both medicines.

Methods: Databases for the search included Pubmed, Embase and the Cochrane Central Register of Controlled Trials. Revman v5.0 statistical program was used to analyze the data. Weighted mean differences (WMD) with a 95% confidence interval (CI) were used for the calculation of continuous data, and relative risk (RR) with a 95% CI was used for dichotomous data.

Results: We analyzed the data from 7 RCTs for a total of 6074 participants in this meta-analysis. We found that the aliskiren/amlodipine combination therapy had a stronger effect in lowering blood pressure as compared with the monotherapy using aliskiren (SBP: WMD = -10.42, 95% CI -13.03∼-7.82, P<0.00001; DBP: WMD = -6.60, 95% CI -7.22∼-5.97, P<0.00001) or amlodipine (SBP: WMD = -4.85, 95% CI -6.88∼-2.81, P<0.00001; DBP: WMD = -2.91, 95% CI -3.85∼-1.97, P<0.00001). No differences were found in terms of adverse events between combination therapy and monotherapy, except for the rates of peripheral edema and hypokalaemia which were significantly lower in the combination therapy than in the amlodipine monotherapy (RR = 0.78, 0.66∼0.92, P = 0.004; RR = 0.51, 0.27∼0.97, P = 0.04). Similar antihypertensive effects were found in both obese (body mass index > = 30 kg/m(2)) hypertensive and non-obese (body mass index <30 kg/m(2)) hypertensive patients. Moreover, there was no difference with the blood pressure lowering or adverse effects with regards to the combination therapy in both subgroups.

Conclusion: We found that aliskiren/amlodipine combination therapy provided a more effective blood pressure reduction than monotherapy with either drug without increase in the occurrence of adverse events.

Citing Articles

Exploratory Studies on RNAi-Based Therapies Targeting Angiotensinogen in Hypertension: Scoping Review.

Junior A, Nogueira T, de Lima K, de Oliveira H, Botelho S J Pers Med. 2025; 15(1).

PMID: 39852196 PMC: 11766978. DOI: 10.3390/jpm15010003.

Efficacy and safety of aliskiren combination therapy: a protocol for an umbrella review.

Shen J, Feng W, Wang Y, Zhao Q, Flavorta B, Lu J BMJ Open. 2021; 11(3):e043807.

PMID: 33687953 PMC: 7944987. DOI: 10.1136/bmjopen-2020-043807.

First-line combination therapy versus first-line monotherapy for primary hypertension.

Garjon J, Saiz L, Azparren A, Gaminde I, Ariz M, Erviti J Cochrane Database Syst Rev. 2020; 2:CD010316.

PMID: 32026465 PMC: 7002970. DOI: 10.1002/14651858.CD010316.pub3.

Renin Inhibition with Aliskiren: A Decade of Clinical Experience.

Pantzaris N, Karanikolas E, Tsiotsios K, Velissaris D J Clin Med. 2017; 6(6).

PMID: 28598381 PMC: 5483871. DOI: 10.3390/jcm6060061.

First-line combination therapy versus first-line monotherapy for primary hypertension.

Garjon J, Saiz L, Azparren A, Elizondo J, Gaminde I, Ariz M Cochrane Database Syst Rev. 2017; 1:CD010316.

PMID: 28084624 PMC: 6464906. DOI: 10.1002/14651858.CD010316.pub2.

References

Braun-Dullaeus R, Shustov S, Alvarez C, Rogelio G, Zhang J, Hristoskova S . Treatment with aliskiren/amlodipine combination in patients with moderate-to-severe hypertension: a randomised, double-blind, active comparator trial. Int J Clin Pract. 2012; 66(9):834-42. DOI: 10.1111/j.1742-1241.2012.02967.x. View

Drummond W, Munger M, Essop M, Maboudian M, Khan M, Keefe D . Antihypertensive efficacy of the oral direct renin inhibitor aliskiren as add-on therapy in patients not responding to amlodipine monotherapy. J Clin Hypertens (Greenwich). 2007; 9(10):742-50. PMC: 8109853. DOI: 10.1111/j.1524-6175.2007.06614.x. View

Wang J, Staessen J, Franklin S, Fagard R, Gueyffier F . Systolic and diastolic blood pressure lowering as determinants of cardiovascular outcome. Hypertension. 2005; 45(5):907-13. DOI: 10.1161/01.HYP.0000165020.14745.79. View

Karas M, Lacourciere Y, LeBlanc A, Nadeau R, Dube B, Florescu M . Effect of the renin-angiotensin system or calcium channel blockade on the circadian variation of heart rate variability, blood pressure and circulating catecholamines in hypertensive patients. J Hypertens. 2005; 23(6):1251-60. DOI: 10.1097/01.hjh.0000170389.69202.53. View

Gradman A, Schmieder R, Lins R, Nussberger J, Chiang Y, Bedigian M . Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients. Circulation. 2005; 111(8):1012-8. DOI: 10.1161/01.CIR.0000156466.02908.ED. View

Moist L . ACP Journal Club. Review: Aliskiren plus ACEIs or ARBs increases hyperkalemia more than aliskiren, ACEIs, or ARBs alone. Ann Intern Med. 2012; 156(12):JC6-9. DOI: 10.7326/0003-4819-156-12-201206190-02009. View

Glorioso N, Thomas M, Troffa C, Argiolas G, Patel S, Baek I . Antihypertensive efficacy and tolerability of aliskiren/amlodipine single- pill combinations in patients with an inadequate response to aliskiren monotherapy. Curr Vasc Pharmacol. 2012; 10(6):748-55. DOI: 10.2174/157016112803520765. View

Littlejohn 3rd T, Jones S, Zhang J, Hsu H, Keefe D . Efficacy and safety of aliskiren and amlodipine combination therapy in patients with hypertension: a randomized, double-blind, multifactorial study. J Hum Hypertens. 2012; 27(5):321-7. DOI: 10.1038/jhh.2012.42. View

Tepel M, Hopfenmueller W, Scholze A, Maier A, Zidek W . Effect of amlodipine on cardiovascular events in hypertensive haemodialysis patients. Nephrol Dial Transplant. 2008; 23(11):3605-12. PMC: 2568006. DOI: 10.1093/ndt/gfn304. View

10.

Imanishi T, Tsujioka H, Ikejima H, Kuroi A, Takarada S, Kitabata H . Renin inhibitor aliskiren improves impaired nitric oxide bioavailability and protects against atherosclerotic changes. Hypertension. 2008; 52(3):563-72. DOI: 10.1161/HYPERTENSIONAHA.108.111120. View

11.

Xu B, Xiao-Hong L, Lin G, Queen L, Ferro A . Amlodipine, but not verapamil or nifedipine, dilates rabbit femoral artery largely through a nitric oxide- and kinin-dependent mechanism. Br J Pharmacol. 2002; 136(3):375-82. PMC: 1573371. DOI: 10.1038/sj.bjp.0704753. View

12.

Lindqvist M, Kahan T, Melcher A, Ekholm M, Hjemdahl P . Long-term calcium antagonist treatment of human hypertension with mibefradil or amlodipine increases sympathetic nerve activity. J Hypertens. 2006; 25(1):169-75. DOI: 10.1097/HJH.0b013e3280104dba. View

13.

Taddei S, Virdis A, Ghiadoni L, Magagna A, Favilla S, Pompella A . Restoration of nitric oxide availability after calcium antagonist treatment in essential hypertension. Hypertension. 2001; 37(3):943-8. DOI: 10.1161/01.hyp.37.3.943. View

14.

Weinberger M, Izzo Jr J, Purkayastha D, Weitzman R, Black H . Comparative efficacy and safety of combination aliskiren/amlodipine and amlodipine monotherapy in African Americans with stage 2 hypertension and obesity or metabolic syndrome. J Am Soc Hypertens. 2011; 5(6):489-97. DOI: 10.1016/j.jash.2011.08.005. View

15.

Oparil S, Yarows S, Patel S, Fang H, Zhang J, Satlin A . Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial. Lancet. 2007; 370(9583):221-229. DOI: 10.1016/S0140-6736(07)61124-6. View

16.

Musini V, Fortin P, Bassett K, Wright J . Blood pressure lowering efficacy of renin inhibitors for primary hypertension: a Cochrane systematic review. J Hum Hypertens. 2009; 23(8):495-502. DOI: 10.1038/jhh.2008.162. View

17.

Kloner R, Sowers J, Dibona G, Gaffney M, Wein M . Effect of amlodipine on left ventricular mass in the Amlodipine Cardiovascular Community Trial. J Cardiovasc Pharmacol. 1995; 26(3):471-6. DOI: 10.1097/00005344-199509000-00018. View

18.

Struck J, Muck P, Trubger D, Handrock R, Weidinger G, Dendorfer A . Effects of selective angiotensin II receptor blockade on sympathetic nerve activity in primary hypertensive subjects. J Hypertens. 2002; 20(6):1143-9. DOI: 10.1097/00004872-200206000-00026. View

19.

Brown M, McInnes G, Papst C, Zhang J, MacDonald T . Aliskiren and the calcium channel blocker amlodipine combination as an initial treatment strategy for hypertension control (ACCELERATE): a randomised, parallel-group trial. Lancet. 2011; 377(9762):312-20. DOI: 10.1016/S0140-6736(10)62003-X. View

20.

Mooser V, Nussberger J, Juillerat L, Burnier M, Waeber B, Bidiville J . Reactive hyperreninemia is a major determinant of plasma angiotensin II during ACE inhibition. J Cardiovasc Pharmacol. 1990; 15(2):276-82. DOI: 10.1097/00005344-199002000-00015. View